Company / Return on Equity (ROE)
Silo Pharma, Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-71.1%
FY2025
5-year range
-248.7% / -37.8%
FY2021-FY2025
Trend
-18.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Silo Pharma, Inc. reports negative total equity of -71.1% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-71.1% in FY2025 with a 5-year CAGR of +177.6%.
Declined from -37.8% to -71.1% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- +177.6pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 18.7% year-over-year.
- Peak return on equity (roe) was recorded in FY2023.
- Lowest return on equity (roe) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -71.1% | -18.7% |
| FY2024 | -59.9% | -58.5% |
| FY2023 | -37.8% | +84.8% |
| FY2020 | -248.7% | -4.5% |
| FY2019 | -237.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026